Investigational drug · Phase 3
GNR-068
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Plaque Psoriasis.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "GNR-068"
First trial start
2023
Jul 25, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GNR-068", any sponsor or status.
Conditions studied
As listed on its trial records.
- Plaque Psoriasis
Approved drugs for the same conditions: Plaque psoriasis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "GNR-068" as an intervention, largest first.
- An Efficacy and Safety Study of GNR-068 (Ustekinumab Biosimilar) and Stelara® in the Treatment of Patients With Moderate to Severe Plaque PsoriasisPivotal-lookingCompleted
AO GENERIUMIndustry
NCT06488664 · 422 participants · Start Jul 25, 2023 · Primary completion Apr 30, 2025
Drug: GNR-068; Stelara® · For: Plaque Psoriasis
Sites: Barnaul, Russia; Chelyabinsk, Russia; Yekaterinburg, Russia · 34 sites in all
- A Safety and Pharmacokinetics Study of Ustekinumab Biosimilar GNR-068 and Stelara® in Healthy VolunteersPivotal-lookingCompleted
AO GENERIUMIndustry
NCT06481215 · 122 participants · Start Mar 11, 2022 · Primary completion Sep 4, 2022
Drug: GNR-068; Stelara® · For: Healthy Volunteers
Sites: Moscow, Russia · 2 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- An Open-Label, Comparative, Parallel Clinical Trial of the Safety, Pharmacokinetics and Immunogenicity of the Ustekinumab Biosimilar GNR-068 and the Originally Developed Ustekinumab as a Reference Drug After a Single Subcutaneous Administration in Healthy Male Volunteers.
Lyagoskin I, Agafonova A, Shevchenko I, et al. · Antibodies (Basel) 2026
Also in development for Plaque Psoriasis
- ZasocitinibTAK- 279, NDI-034858Phase 317 trials
Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease
- TLL-018Phase 38 trials
Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria
- EnvudeucitinibPhase 34 trials
Alumis Inc · Plaque Psoriasis, SLE
- ICP-332Phase 34 trials
Beijing InnoCare Pharma Tech Co., Ltd. · Non Segmental Vitiligo, Chronic Spontaneous Urticaria (CSU), Atopic Dermatitis
- TQH3906Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Psoriasis, Systemic Lupus Erythematosus, Psoriatic Arthritis
- NetakimabPhase 32 trials
Biocad · Plaque Psoriasis
- PicankibartPhase 32 trials
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Psoriatic Arthritis, Plaque Psoriasis
- piclidenosonPhase 32 trials
Can-Fite BioPharma · Plaque Psoriasis, Lowe Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.